TG Therapeutics (NASDAQ:TGTX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Volatility & Risk
TG Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
Insider and Institutional Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares TG Therapeutics and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 11.81% | 18.82% | 7.78% |
| ProKidney | -10,288.39% | N/A | -27.39% |
Valuation and Earnings
This table compares TG Therapeutics and ProKidney”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $616.29 million | 15.83 | $447.18 million | $0.66 | 97.82 |
| ProKidney | $890,000.00 | 390.64 | -$68.99 million | ($0.55) | -2.09 |
TG Therapeutics has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for TG Therapeutics and ProKidney, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| ProKidney | 1 | 0 | 2 | 1 | 2.75 |
TG Therapeutics currently has a consensus price target of $63.00, indicating a potential downside of 2.42%. ProKidney has a consensus price target of $10.00, indicating a potential upside of 769.57%. Given ProKidney’s higher probable upside, analysts plainly believe ProKidney is more favorable than TG Therapeutics.
Summary
TG Therapeutics beats ProKidney on 9 of the 13 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
